Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10

作者：

Kondagunta, GV

Bacik, J

Schwartz, L

Sheinfeld, J

Bajorin, D

Vuky, J

Marion, S

Mazumdar, M

Bosl, GJ

Motzer, RJ

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA

来源：

INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期

关键词：

temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;

D O I：

10.1023/B:DRUG.0000011794.21608.59

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

引用

页码：177 / 179

页数：3

共 50 条

[41] Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial
Wierzbicka-Hainaut, Ewa
Sassolas, Bruno
Mourey, Laurent
Guillot, Bernard
Bedane, Christophe
Guillet, Gerard
Tourani, Jean Marc
MELANOMA RESEARCH, 2010, 20 (02) : 141 - 146
[42] Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Reynes, Gaspar
Martinez-Sales, Vicenta
Vila, Virtudes
Balana, Carmen
Perez-Segura, Pedro
Vaz, Maria A.
Benavides, Manuel
Gallego, Oscar
Palomero, Isabel
Gil-Gil, Miguel
Fleitas, Tania
Reche, Encarnacion
ANTI-CANCER DRUGS, 2016, 27 (02) : 133 - 137
[43] Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
Adra, N.
Einhorn, L. H.
Althouse, S. K.
Ammakkanavar, N. R.
Musapatika, D.
Albany, C.
Vaughn, D.
Hanna, N. H.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 209 - 214
[44] A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma
Zustovich, Fable
Lombardi, Giuseppe
Della Puppa, Alessandro
Rotilio, Antonino
Scienza, Renato
Pastorelli, Davide
ANTICANCER RESEARCH, 2009, 29 (10) : 4275 - 4279
[45] A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors
Zustovich, Fable
Cartei, Giuseppe
Ceravolo, Renato
Zovato, Stefania
Della Puppa, Alessandro
Pastorelli, Davide
Mattiazzi, Martina
Bertorelle, Roberta
Gardiman, Marina Paola
ANTICANCER RESEARCH, 2007, 27 (02) : 1019 - 1024
[46] A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Nabil Adra
David J. Vaughn
Lawrence H. Einhorn
Nasser H. Hanna
Samuel A. Funt
Matt Rosales
Ahsan Arozullah
Darren R. Feldman
Investigational New Drugs, 2022, 40 : 1087 - 1094
[47] A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Adra, Nabil
Vaughn, David J.
Einhorn, Lawrence H.
Hanna, Nasser H.
Funt, Samuel A.
Rosales, Matt
Arozullah, Ahsan
Feldman, Darren R.
INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1087 - 1094
[48] A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma
Talbot, SM
Keohan, ML
Hesdorffer, M
Orrico, R
Bagiella, E
Troxel, AB
Taub, RN
CANCER, 2003, 98 (09) : 1942 - 1946
[49] Management of Stage II Germ Cell Tumors
Ghandour, Rashed A.
Singla, Nirmish
Bagrodia, Aditya
UROLOGIC CLINICS OF NORTH AMERICA, 2019, 46 (03) : 363 - +
[50] Prognostic factors in patients with relapsed or primary refractory germ cell tumors
Rejlekova, K.
Mego, M.
Sycova-Mila, Z.
Obertova, J.
Rajec, J.
Salek, T.
Mardiak, J.
NEOPLASMA, 2009, 56 (03) : 215 - 223

← 1 2 3 4 5 →